Dr. Ramelmeier joined BioMarin in September 2006 as Vice President of Manufacturing and Process Development. His responsibilities include oversight of manufacturing, manufacturing sciences, process development, and facilities. Prior to joining BioMarin, Dr. Ramelmeier was Vice President, Process Sciences, of the Global Biologics Supply Chain (formerly Centocor Inc.) at Johnson & Johnson. In this role, he oversaw technical support of J&J's BioPharm manufacturing plants, including process validation and tech transfer of new and existing products, regulatory inspections, and process improvements. From 2001 to 2005, he served as Executive Director, Pharmaceutical Development at Centocor, where he was responsible for pilot plant operations, clinical and toxicology supplies, and pilot-scale process development. In this role, his team increased clinical manufacturing capacity three-fold and developed scale-up capability to meet the growing needs of the BioPharm business in J&J. Earlier in his career, Dr. Ramelmeier was Senior Research Fellow, Bioprocess Research and Development at Merck & Co.

Michael Teasdale is Senior Director, Operational Excellence for Baxter BioScience, a 5 billion dollar biotech division of Baxter. He has been in this role since 2002, driving strategic planning, divisional dashboards, and a Lean Six Sigma roll out and organization. The initiative Michael leads has yielded more than 250 million dollars in benefit. Before joining Baxter Michael worked 6 years with GE Medical Systems. His last role there was developing and leading a global initiative to bring Six Sigma to healthcare providers. This effort brought more than $60m in benefit with over 2000 projects to healthcare providers across the world.

Jim Kasselmann is a Director at Genentech where he leads their Clinical Manufacturing operations as well as serving on the site leadership team at their Oceanside, CA campus. Before this role he was the Director for Production Services where he led all Oceanside production operations to attaining Oliver Wight certification as “Class A” in operational excellence. He also led the Quality Control testing laboratories for two years; overseeing start-up testing and qualifications for commercial operations. Prior to working for Genentech he worked for Biogen Idec and IDEC. Jim also had a twenty-year career serving as an officer in the United States Marine Corps, specializing in logistics; he retired from the Marines in 2002 as a Lieutenant Colonel.

Thomas holds a Ph.D. in chemical engineering from the University of Stuttgart in Germany. He joined Bayer in Leverkusen in 1991, spent 5 years in the Central Technology Department and moved on to become a production lead for the Polyester unit in Dormagen (Germany). In 1999 he got an assignment in the CESRO office in Baytown, TX and became 2002 Head of the Process Technology Group of Bayer Technology Services in America. Since 2007 he is heading the BTS Product Group Applied Science and Biotechnology. Consolidating and streamlining the efforts of the BTS-Healthcare activities he relocated 2009 to Bayer’s Biotech production location in Berkeley California and became V.P. of BTS-A Process Technology Healthcare.

Advisory board member only
Pharmaceutical Professional with 21 years of experience in the Technical and Commercial funtions of Pharmaceutical Finished Dosage Forms.Has experience in most of the Dosage forms which includes Tablets,Capsules,Soft Gelatin Capsules, Liquid and Dry Powder Injections,Liquids,Creams and Ointments and Nasal Spray.Have been working in the Senior Managment positions as Head of Multiple locations since 11 years.Served for Companies of varied sizes from Mid segment to Large corporates and TransNational Organizations and has versatile experience in handling Organizational issues. Designed and Developed 5 Finished Dosage Manufacturing Plants.